June 22, 2022, 10:34 PM
Merck says the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted to include Vaxneuvance as a recommended option for vaccination in infants and children, including routine use in children under 2 years of age.
- The committee unanimously voted to include Vaxneuvance in the Vaccines for Children program
- Vaxneuvance is the first new pneumococcal conjugate vaccine for pediatric populations to be recommended in almost a decade
NOTE
- Merck & Co. rose 0.6% in postmarket trading to $89.73 as of 6:29 p.m. New York time
- The average 12-month price target of $96.95 is 8.1% above the …
